Sickle Cell Disease Financial Planning: SSDI, Gene Therapy Strategy, and SNT Planning

Sickle cell disease creates a distinctive financial planning challenge that cuts in two directions simultaneously. On one side: most adults with SCD want to work and can work — at least some of the time — which means financial planning is about preserving Medicaid and other benefits while maximizing earned income, not simply about qualifying for disability benefits. On the other side: two FDA-approved gene therapies — priced at $2.2 million and $3.1 million per patient — offer the possibility of a functional cure, but only for patients whose insurance coverage is intact when they need it. An adult with SCD who lets Medicaid lapse to work more hours, then loses their job during a pain crisis, may lose their place in the gene therapy access pipeline precisely when they need it most. This guide covers both sides of that equation: SSDI and SSI benefit rules, Section 1619(b) Medicaid protection for working adults, the gene therapy financial planning decision, ongoing medication cost structure, and how Special Needs Trusts and ABLE accounts fit into a complete plan for SCD adults and their families.

Who this affects: SCD prevalence and the planning population

Sickle cell disease affects approximately 100,000 people in the United States. More than 90% are non-Hispanic Black or African American; an estimated 3–9% are Hispanic or Latino. SCD occurs in approximately 1 out of every 365 Black or African American births.¹ The planning population for this guide is broad: adults with SCD who are navigating work, benefits, and long-term financial planning; parents and family members structuring inheritances and SNTs to protect an SCD family member's government benefits; and families evaluating gene therapy financing and insurance strategy.

SCD is a spectrum condition. Adults with hemoglobin SS (HbSS) disease — the most common and severe form — face the highest lifetime complication burden: frequent vaso-occlusive (pain) crises, acute chest syndrome, stroke, avascular necrosis, renal and cardiac complications, and organ damage that accumulates over decades. Adults with HbSC disease or HbS-beta thalassemia generally have milder presentations, though serious complications occur across the spectrum. This planning guide is most directly relevant to HbSS adults with significant disease burden, though many principles apply across SCD genotypes.

SSDI under SSA Blue Book Listing 7.05

Adults with SCD who cannot sustain substantial gainful activity due to their disease qualify for Social Security Disability Insurance under Section 7.05 of the SSA's Blue Book — the official Listing of Impairments for hematological disorders. Unlike Huntington's disease or ALS, sickle cell disease is not on the SSA's Compassionate Allowances list, meaning applications are processed through standard review rather than a 10-day fast-track. The Blue Book provides three pathways to automatic approval:

7.05A: Vaso-occlusive (pain) crises

This pathway requires documented painful vaso-occlusive crises requiring parenteral (intravenous or intramuscular) narcotic medication, occurring at least six times within a 12-month period, with at least 30 days between crises.²

Two documentation points matter in practice: First, "parenteral narcotic" means IV or IM administration — a prescription for oral pain medications, even opioids taken at home, does not satisfy this criterion. The crisis must have required hospital or emergency department-level treatment with parenteral narcotics. Second, the 30-day separation requirement exists specifically to prevent a single prolonged crisis from counting as multiple events. An SCD adult who has frequent pain crises managed partially at home should work with their hematologist to ensure every crisis requiring parenteral treatment is documented in the medical record, because underdocumented crises are the most common reason 7.05A applications are denied despite genuine severity.

7.05B: Complications of hemolytic anemia

This pathway has two alternative qualifying sub-criteria:

• 7.05B(i) — Hospitalizations: Complications of SCD requiring at least three hospitalizations within a 12-month period, with at least 30 days between hospitalizations, each lasting at least 48 hours. The 48-hour count can include hours spent in a hospital emergency department or comprehensive sickle cell disease center immediately before formal inpatient admission. Qualifying complications include acute chest syndrome, osteomyelitis, pulmonary infections or infarctions, pulmonary hypertension, chronic heart failure, hepatic failure, renal failure, nephrotic syndrome, aplastic crisis, and stroke.
• 7.05B(ii) — Hemoglobin: Hemoglobin measurements of 7.0 g/dL or less, occurring at least three times within a 12-month period, with at least 30 days between measurements. This pathway requires documented lab values in the medical record — not physician estimates or clinical impressions. An SCD adult who chronically runs hemoglobin in the 6–7 g/dL range and has labs drawn regularly should ensure those values are in their treatment records before applying.

7.05C: Beta-thalassemia major

This pathway is specific to beta-thalassemia major requiring lifelong red blood cell transfusions at least once every six weeks to maintain life. It is distinct from the SCD criteria but appears in the same 7.05 listing because it affects the same SSA hematological disorder framework. SCD adults with sickle beta-thalassemia (HbS-beta-0 thalassemia) may qualify under 7.05C if they require transfusions at this frequency, or under 7.05A or 7.05B if pain crises or complications are the primary disabling feature.

Medical-vocational grid for SCD adults who don't meet a listing

An SCD adult who doesn't meet the Blue Book criteria — perhaps because crises are frequent but don't consistently reach the parenteral-narcotic threshold, or because hemoglobin is chronically low but not quite at 7.0 g/dL — may still qualify under SSA's medical-vocational grid. This analysis considers the adult's residual functional capacity (RFC), age, education, and past work to determine whether any jobs exist in the national economy that the adult can perform despite their limitations. Pain-related functional limitations, medication side effects, attendance issues from unpredictable crises, and fatigue from chronic anemia are all RFC factors. An attorney or advocate experienced in SCD cases can substantially improve approval rates for grid-based applications.

SSDI timeline: the Medicare gap

SSDI entitlement carries a 5-month waiting period from the established disability onset date, followed by a 24-month waiting period before Medicare coverage begins — 29 months total. For an SCD adult transitioning from employer health insurance to SSDI, this gap requires a bridge strategy:

• COBRA disability extension (29 months): When SSA determines that disability existed at or before the date of job loss or reduction in hours, the standard 18-month COBRA continuation period extends to 29 months — precisely covering the Medicare gap. COBRA premiums apply in full (typically $600–$1,500+/month). For an SCD adult who needs crizanlizumab infusions ($85,000–$113,000/year) or other specialty medications during this period, maintaining prior employer coverage through COBRA may be significantly more cost-effective than paying drug costs out-of-pocket on an ACA marketplace plan.
• ACA marketplace plan: ACA marketplace plans cannot deny coverage or impose pre-existing condition exclusions for SCD. Advanced premium tax credits reduce cost substantially for SCD adults with low income during the SSDI gap year.
• Medicaid: If the SCD adult has income below their state's Medicaid threshold and limited countable assets, Medicaid may cover them during the SSDI gap. Once SSDI is approved, SSI eligibility typically ends if SSDI is higher than SSI, but Medicaid may continue under a state Medicaid buy-in or other provision depending on income. The key insurance continuity principle for SCD adults with gene therapy on the horizon: do not allow any coverage gap around the time of gene therapy evaluation and treatment.

SSI and Section 1619(b): the working SCD adult's most important tool

Many adults with SCD work — sometimes full-time, sometimes part-time, and sometimes inconsistently due to pain crises. SSI provides a floor benefit ($994/month in 2026) and, more importantly, Medicaid eligibility. Section 1619(b) of the Social Security Act protects Medicaid even when earned income exceeds the Substantial Gainful Activity (SGA) threshold of $1,690/month.³

How Section 1619(b) works

An SSI recipient who earns above SGA does not automatically lose Medicaid. Instead, they enter Section 1619(b) status, under which Medicaid continues as long as:

• The person continues to have a disabling impairment (SCD continues to meet the disability standard);
• The person needs Medicaid to continue working (a low threshold — the need to maintain insurance for SCD-related treatment easily satisfies this);
• The person's income does not exceed their state's individual 1619(b) threshold — a state-specific dollar amount calculated annually, typically ranging from approximately $30,000 to $60,000 or more per year depending on the state's Medicaid spending per disabled beneficiary.

For an SCD adult working part-time or with variable hours due to pain crises, Section 1619(b) means they can earn substantially above the $1,690/month SGA limit without losing Medicaid — and therefore without losing access to the Medicaid-covered gene therapy pipeline, crizanlizumab infusions, and other high-cost treatments. SSA should be notified of any changes in earnings, and the SCD adult should confirm their state's current 1619(b) threshold annually with an SSA representative or special needs financial planner.

SSI earned income formula and the break-even calculation

SSI uses a specific earned income formula that gives SCD adults more working room than many realize. SSA first excludes the general income exclusion ($20/month from any income) and the earned income exclusion ($65/month from earned income), then counts only half of remaining earned income against the SSI payment. The math:

• Break-even earned income (where SSI payment reaches $0): approximately $2,065/month in 2026 for a single adult with no unearned income
• At $2,065/month earned income, SSI payments end — but Section 1619(b) Medicaid protection continues beyond this point, up to the state 1619(b) threshold

For an SCD adult who works when health permits and stops working during extended pain crises, this formula also allows reinstatement of SSI payments when earnings fall below the break-even — without a new disability determination, as long as the disabling condition continues. Expedited Reinstatement (EXR) is available for adults who lose SSI due to earnings and then need to restart within five years.

Gene therapy: the $2.2M–$3.1M financial planning decision

Two gene therapies for sickle cell disease received FDA approval in December 2023: Casgevy (exagamglogene autotemcel, developed by Vertex Pharmaceuticals and CRISPR Therapeutics) at a list price of $2.2 million per patient, and Lyfgenia (lovotibeglogene autotemcel, developed by bluebird bio) at $3.1 million per patient.⁴ Both are one-time treatments that involve harvesting the patient's own blood stem cells, genetically modifying them, and reinfusing them after a conditioning regimen. Clinical trials have shown over 88% of patients free from severe vaso-occlusive events after treatment.

At these price points, self-pay is not a realistic option for the overwhelming majority of SCD adults. The financial planning question for gene therapy is not "how do I pay $2–3 million" but rather "how do I ensure I remain covered by an insurer — Medicaid, a commercial plan, or both — when I need it."

Medicaid as the primary payer: the CMS CGT Access Model

Because more than half of SCD adults in the United States are covered by Medicaid, CMS created the Cell and Gene Therapy (CGT) Access Model, which began rolling out in January 2025. By 2026, 33 states plus the District of Columbia and Puerto Rico have joined the model, representing approximately 84% of the total Medicaid SCD population.⁴ Under this model, CMS negotiates outcomes-based agreements with Vertex (Casgevy) and bluebird (Lyfgenia) on behalf of participating state Medicaid programs. The outcomes-based structure means payments are tied to treatment efficacy over time — reducing the up-front financial risk that previously deterred Medicaid programs from covering these therapies.

For an SCD adult in a participating state who is Medicaid-eligible: gene therapy is accessible through Medicaid under the CGT Access Model. The financial planning imperative is to maintain continuous Medicaid eligibility through the evaluation, conditioning, and recovery process — which can span 12–18 months from initial evaluation to full recovery. A coverage gap during conditioning (which involves chemotherapy to destroy existing bone marrow cells) would be medically catastrophic and financially devastating.

Commercial insurance coverage

For SCD adults on commercial insurance through an employer, gene therapy coverage depends on the plan's benefit design. Large self-insured employer plans increasingly cover Casgevy and Lyfgenia, though prior authorization requirements, center-of-excellence restrictions (treatment must occur at an approved treatment facility), and step therapy protocols (requiring hydroxyurea failure first) vary by plan. ACA marketplace plans are not required to cover experimental treatments, though they may choose to do so. The key commercial insurance planning steps:

• Verify gene therapy benefits and prior authorization requirements with your specific plan before beginning the evaluation process — not mid-process.
• Ensure employer group coverage will remain intact throughout treatment. A job change, layoff, or reduction in hours mid-treatment creates a coverage gap risk.
• Understand COBRA rights if employment changes during treatment — the disability extension to 29 months applies if SSA has established disability.

The insurance timing problem: don't let coverage lapse

The gene therapy pipeline moves slowly. An SCD adult who decides to pursue gene therapy may wait months for evaluation, months more for a treatment slot at an approved center, and then undergo conditioning and infusion over weeks. The total elapsed time from decision to completed treatment is typically 12–24 months or more. An SCD adult who allows Medicaid to lapse — by earning above the 1619(b) threshold, by receiving a direct inheritance that pushes assets above the $2,000 SSI resource limit, or by failing to recertify SSI — may lose their Medicaid slot in the CGT Access Model queue at a point when requalifying takes months. Financial planning around gene therapy means treating Medicaid continuity as the primary constraint and building every other financial decision around it.

Ongoing SCD medication costs

For SCD adults who are not yet candidates for gene therapy or who choose to manage the disease medically, the current 2026 medication landscape includes:

• Hydroxyurea: A decades-old generic medication that reduces the frequency of pain crises and acute chest syndrome in HbSS disease. Generic hydroxyurea costs approximately $500–$2,000/year — affordable for most payers and accessible through most formularies. It is the standard first-line disease-modifying agent and is required as a prior treatment step by some insurance plans before authorizing newer therapies.
• Crizanlizumab (Adakveo): A monthly IV infusion (P-selectin inhibitor) that reduces vaso-occlusive crises. List price approximately $85,000–$113,000/year. Requires infusion center visits monthly. A prior authorization step on most commercial plans; Medicaid coverage varies by state. For SCD adults on Medicaid in non-CGT Access Model states, crizanlizumab access may require Medicaid appeals.
• L-glutamine (Endari): An oral supplement approved for SCD, priced at approximately $36,000/year at list price. Reduces frequency of acute complications. Less commonly used than crizanlizumab due to cost-to-benefit debates, but covered under some plans.

The 2026 Medicare Part D out-of-pocket cap of $2,100 per year benefits SCD adults on Medicare who take expensive oral specialty drugs. Medicare Part B covers crizanlizumab infusions under the physician-administered drug benefit (not Part D), subject to 20% coinsurance — which makes a supplemental (Medigap) policy or Medicaid as a payer important for SCD adults relying on crizanlizumab infusions under Medicare.

Special Needs Trust planning for SCD families

An SCD adult who receives SSI and Medicaid is subject to the SSI $2,000 countable resource limit. Any inheritance, gift, or settlement paid directly to the SCD adult that pushes their countable resources above $2,000 will end SSI and, critically, end Medicaid — including the gene therapy pipeline access it provides. SNT planning prevents this.

Third-party SNT: parents and family members protecting an SCD adult on SSI

A third-party Special Needs Trust holds assets left by parents, grandparents, or siblings for an SCD beneficiary. Assets in the trust do not count toward the SSI $2,000 resource limit. Distributions from the trust for supplemental expenses — pain management devices, transportation to sickle cell treatment centers, dietary supplements, travel to CRISPR or gene therapy evaluation appointments, home modifications for accessibility during pain crises — do not destroy SSI or Medicaid as long as the trustee avoids distributions for food and shelter (which create In-Kind Support and Maintenance (ISM) reductions in the SSI payment).

For parents of an SCD adult on SSI, all estate planning documents must be updated to route assets through the third-party SNT rather than to the SCD adult directly. This includes:

• Will bequests — direct bequests to an SSI recipient destroy benefits instantly upon receipt
• Life insurance beneficiary designations — the trust, not the SCD adult, should be named
• IRA and 401(k) beneficiary designations — see the Retirement Accounts and Special Needs guide for the SECURE Act disabled EDB rules that allow lifetime stretch through a properly structured trust
• Transfer-on-death and payable-on-death account designations

Unlike some conditions where the SNT planning horizon is 40–60 years, SCD planning requires modeling the gene therapy scenario alongside the non-gene-therapy scenario: if the SCD adult receives Casgevy or Lyfgenia and achieves functional cure, their long-term benefit dependency may end — the SNT structure remains appropriate as a legal vehicle but the funding need decreases substantially. Discuss with a special needs planner how to structure the trust to accommodate both scenarios.

First-party SNT: when an SCD adult receives direct assets

A first-party SNT (d4A trust, established under 42 U.S.C. § 1396p(d)(4)(A)) is used when an SCD adult on SSI/Medicaid receives assets that would otherwise destroy benefit eligibility — most commonly through a personal injury settlement (e.g., a medical malpractice claim related to SCD mismanagement or delayed diagnosis), a direct inheritance from a family member who did not have a third-party SNT, or another windfall. Requirements:

• The SCD adult must be under 65 at the time the trust is established
• The trust must be established by a parent, grandparent, legal guardian, or court
• The trust must include a Medicaid payback provision — upon the beneficiary's death, any remaining assets must be used to reimburse the state Medicaid agency for benefits paid during the beneficiary's lifetime, before distribution to heirs

If a gene therapy treatment is funded entirely by Medicaid under the CGT Access Model, the Medicaid agency will have a substantial reimbursement claim at death (potentially $2+ million for the gene therapy alone). First-party SNT planning for SCD adults should model the Medicaid payback exposure as part of the estate plan.

See the First-Party vs Third-Party SNT guide for the complete mechanics of each structure.

ABLE account for SCD adults

An ABLE account allows SCD adults who receive SSI to save beyond the $2,000 SSI resource limit without losing benefits. Key 2026 ABLE rules for SCD adults:⁵

• Age eligibility: Disability onset before age 46 (ABLE Age Adjustment Act, effective January 2026). SCD is a congenital condition for the vast majority of individuals — onset from birth — so virtually all adults with SCD qualify regardless of current age, as long as the disability is established.
• Annual contribution limit: $20,000 from all sources in 2026.
• ABLE-to-Work: SCD adults who work can contribute an additional $15,650 from earned income above the standard limit — especially valuable for SCD adults who work variable schedules and want to accumulate savings during good-health earning months.
• SSI protection: ABLE account balances up to $100,000 do not count toward the SSI $2,000 resource limit. Balances above $100,000 do count, but only the excess reduces the SSI payment (not terminates it).

Qualified disability expenses for SCD adults that can be paid from ABLE accounts without affecting SSI include: transportation to sickle cell treatment centers and infusion appointments, health and wellness expenses (co-pays, OTC pain management aids, dietary supplements), home modifications for accessibility during pain crises, assistive technology, and financial management services. The ABLE account does not replace the SNT — the ABLE account gives the SCD adult direct control over funds for recurring disability expenses, while the SNT holds larger inherited or insurance amounts under trustee management.

Life insurance: parent planning and the rated-premium reality

Parents of an SCD adult who want to fund a third-party SNT typically rely on life insurance as the primary funding vehicle — particularly survivorship (second-to-die) policies that pay out after both parents die and the SNT becomes the primary financial resource for the SCD adult. See the Life Insurance for Special Needs Trusts guide for survivorship policy mechanics.

SCD adults themselves face significant life insurance challenges. Standard individual life insurance is difficult or impossible to obtain for adults with HbSS disease at standard rates — SCD substantially shortens life expectancy in actuarial tables, and many carriers will rate the policy heavily or decline outright. Group life insurance through an employer — which typically requires no individual medical underwriting for basic amounts during open enrollment — is the most accessible life insurance path for SCD adults. Employer group coverage of 1–2× salary provides some death benefit without individual underwriting, though coverage amounts may be limited. If an SCD adult has financial dependents (children, a disabled sibling), the inability to obtain private life insurance at standard rates is a financial planning constraint that should be addressed as part of the overall plan.

HCBS waiver considerations

HCBS (Home and Community Based Services) Medicaid waiver services are most relevant for SCD adults with severe complications — stroke sequelae with lasting cognitive or motor deficits, avascular necrosis requiring mobility assistance, or chronic organ damage requiring personal care support. For SCD adults without lasting functional impairments, the HCBS waiver is less central than for congenital developmental disability planning. However, SCD adults who experience strokes (which affect approximately 11% of HbSS adults by age 20, and can occur later in life from silent infarcts and overt strokes) should apply for HCBS physical disability waiver services immediately following the acute event — waitlists are often 3–10+ years long, and applying after a stroke while the applicant has immediate care needs is still important to establishing a waitlist position for future care needs. See the HCBS Medicaid Waiver guide for enrollment strategy.

Priority actions for SCD adults and families

1. Understand your Section 1619(b) threshold before changing your work hours. If you are an SCD adult on SSI and Medicaid who is considering working more, get your state's current Section 1619(b) threshold from SSA before you change your earnings. You may be able to earn $40,000–$60,000+/year and still retain Medicaid under 1619(b). Losing Medicaid to earn an extra $5,000 in SSI is almost always the wrong trade — particularly for adults with gene therapy on the horizon.
2. If you are a Medicaid-enrolled SCD adult in a CGT Access Model state, treat Medicaid continuity as a first priority. Verify that your state participates in the CMS Cell and Gene Therapy Access Model. If it does, your Medicaid plan covers gene therapy access under outcomes-based agreements with Vertex and bluebird bio. Maintain continuous Medicaid eligibility. Do not allow resources to accumulate above the $2,000 SSI limit without moving excess into an ABLE account or an SNT first.
3. Open an ABLE account. An ABLE account lets you accumulate up to $100,000 above the $2,000 SSI resource limit. Contribute during working months and use it for disability-related expenses — transportation to treatment, co-pays, health management tools. The ABLE-to-Work additional contribution ($15,650 from earned income) is especially valuable for variable earners.
4. Update all beneficiary designations to route through an SNT. Parents of an SCD adult on SSI must name the SNT — not the SCD adult directly — on all retirement accounts, life insurance policies, and transfer-on-death designations. A direct inheritance destroys SSI and Medicaid the moment it exceeds $2,000 in countable resources. This is a correctable mistake if caught immediately, but requires an attorney and court action. Prevent it with correct beneficiary designations now.
5. If you receive a personal injury settlement while on SSI, contact a special needs attorney immediately before the check is issued. A settlement paid directly to an SSI recipient in excess of $2,000 triggers immediate loss of SSI and Medicaid. A first-party SNT must be established before the check is issued or the money is deposited. If the settlement is related to SCD mismanagement, an attorney experienced in first-party SNT establishment and Medicaid payback can preserve both the settlement proceeds and the beneficiary's benefits.
6. If you are not yet on SSI/SSDI and are struggling to sustain work due to SCD, evaluate your Blue Book eligibility. Especially if you have frequent pain crises requiring ED visits with parenteral narcotics, or three or more hospitalizations per year for SCD complications, you may meet Listing 7.05A or 7.05B. An SSDI attorney or advocate with SCD experience can assess your records and identify documentation gaps before you file. The 5-month waiting period means the earlier you file, the earlier benefits begin if approved.
7. Bridge the Medicare gap with COBRA or Marketplace coverage. If you are approved for SSDI and transitioning off employer insurance, the 29-month Medicare gap requires a bridge. The COBRA disability extension to 29 months is your most complete option if you need continued access to specialty medications at employer-plan rates. Get your SSDI approval letter to HR and your COBRA administrator immediately — extension elections must be timely.
8. Work with a fee-only special needs financial planner who understands SCD's dual financial planning profile. SCD planning requires simultaneous fluency in disability benefits, gene therapy coverage mechanics, SNT structure, and work-incentive optimization — a combination that generalist planners rarely have. A fee-only planner with special needs specialization can model both the gene-therapy-achieved and gene-therapy-not-achieved scenarios, ensure your benefits structure is optimized for both outcomes, and coordinate with your estate attorney on trust structure.

Sources

1. CDC — Data and Statistics on Sickle Cell Disease. Sickle cell disease affects approximately 100,000 people in the United States. More than 90% are non-Hispanic Black or African American; an estimated 3–9% are Hispanic or Latino. SCD occurs in approximately 1 out of every 365 Black or African American births and about 1 in 16,300 Hispanic American births. SCD is the most common inherited blood disorder in the United States. Newborn screening is universal in the U.S.; virtually all SCD cases are identified at birth.
2. SSA Blue Book — 7.00 Hematological Disorders, Adult, including Listing 7.05. Section 7.05: Hemolytic anemias, including sickle cell disease, thalassemia, and their variants. Three qualifying pathways: 7.05A — documented painful (vaso-occlusive) crises requiring parenteral narcotic medication, occurring at least six times within a 12-month period, at least 30 days between crises; 7.05B — (i) complications requiring at least three hospitalizations in a 12-month period, at least 30 days apart, each lasting at least 48 hours (including ED/sickle cell center hours immediately preceding admission), OR (ii) hemoglobin measurements of 7.0 g/dL or less at least three times in a 12-month period with at least 30 days between measurements; 7.05C — beta thalassemia major requiring lifelong RBC transfusions at least once every 6 weeks. 2026 SGA threshold: $1,690/month (non-blind), $2,830/month (blind). SCD is not on the SSA Compassionate Allowances list as of 2026; applications processed through standard Blue Book review (typical 3–6 month adjudication).
3. SSA — Section 1619(b) Medicaid Protection for Working Individuals. Section 1619(b) allows SSI recipients whose earned income exceeds the Substantial Gainful Activity threshold ($1,690/month in 2026) to continue receiving Medicaid as long as: (1) disability continues; (2) the individual needs Medicaid to maintain employment; and (3) income does not exceed the state's individual Section 1619(b) threshold. State thresholds are calculated annually based on Medicaid spending and vary by state — typically $30,000–$60,000+ per year. Expedited Reinstatement (EXR) available within 5 years if SSI is lost due to earnings and then re-needed. SSI earned income formula: general exclusion ($20/month), earned income exclusion ($65/month), 50% of remaining earned income counted; break-even approximately $2,065/month earned income at 2026 FBR of $994/month.
4. FDA — FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease (December 2023). FDA approved Casgevy (exagamglogene autotemcel, Vertex Pharmaceuticals / CRISPR Therapeutics) and Lyfgenia (lovotibeglogene autotemcel, bluebird bio) in December 2023 for sickle cell disease. List prices: Casgevy $2.2M per patient; Lyfgenia $3.1M per patient. Clinical trials showed 88%+ of patients free from severe vaso-occlusive events after treatment. CMS Cell and Gene Therapy (CGT) Access Model launched January 2025: as of 2026, 33 states plus DC and Puerto Rico participate (~84% of Medicaid SCD population). Under the CGT Access Model, CMS negotiates outcomes-based payment agreements with manufacturers on behalf of participating state Medicaid programs. Voxelotor (Oxbryta, Pfizer) was voluntarily withdrawn from all markets in September 2024 due to safety concerns (imbalance in vaso-occlusive crises and fatal events); it is no longer available in the United States.
5. ABLE National Resource Center — 2026 Contribution Limits and Eligibility. Annual ABLE contribution limit: $20,000 from all sources (2026). ABLE-to-Work: working beneficiaries may contribute additional amount up to federal poverty level for one-person household ($15,650 in 2026) from earned income. Age eligibility: disability onset before age 46, effective January 2026 (ABLE Age Adjustment Act). SSI protection: ABLE account balance up to $100,000 does not count toward SSI's $2,000 resource limit; balance above $100,000 reduces SSI payment dollar-for-dollar but does not terminate eligibility. Qualified disability expenses include health and wellness, transportation, assistive technology, housing, education, employment training, and financial management. Medicaid payback applies to ABLE accounts at beneficiary's death for states that provided Medicaid. Any state's ABLE plan is available to any eligible beneficiary regardless of state of residence.

Rules verified against 2026 SSA, CMS, and ABLE standards. SSI FBR $994/month; SSI resource limit $2,000 (2026). SSDI SGA $1,690/month non-blind; $2,830/month blind (2026). ABLE contribution limit $20,000/year; ABLE-to-Work additional $15,650/year; age eligibility onset before 46 (all 2026). Gene therapy prices: Casgevy $2.2M (Vertex/CRISPR Therapeutics); Lyfgenia $3.1M (bluebird bio). CMS CGT Access Model: 33 states + DC + PR as of 2026 (~84% Medicaid SCD population). Voxelotor (Oxbryta) withdrawn September 2024 — not available. SCD prevalence: ~100,000 Americans; 90%+ non-Hispanic Black/African American. SSA Blue Book Listing 7.05: three qualifying pathways for hemolytic anemias including SCD. Section 1619(b) Medicaid protection: continues above SGA threshold up to state-specific annual income threshold. This guide does not constitute financial, legal, tax, or insurance advice.